Zoetis Inc. reported its financial results for the second quarter of 2026, revealing a slight decline in revenue and net income compared to the same period in 2025. The company generated $2.468 billion in revenue for the three months ended June 30, 2026, a decrease of 0.2% from $2.474 billion in the prior year. For the first half of 2026, revenue increased by 1.2% to $4.730 billion, compared to $4.672 billion in the same period of 2025. Net income attributable to Zoetis was $691 million for the second quarter, down 4.8% from $726 million a year earlier, while net income for the first half of 2026 was $1.292 billion, a decrease of 2.7% from $1.328 billion in 2025.
The company's operational performance was impacted by a 3% volume decrease from key franchises and the divestiture of its medicated feed additive portfolio, which contributed to a 2% decline in operational revenue. However, foreign exchange fluctuations positively affected total revenue by approximately 2%, adding $35 million in the second quarter. The U.S. segment saw a 7% decline in revenue, primarily due to decreased sales in companion animal products, while the international segment experienced an 8% increase in revenue, driven by growth in both companion animal and livestock products.
In terms of strategic developments, Zoetis announced its intention to acquire Neogen Corporation's animal genomics business, with the transaction expected to close in the second half of 2026. The company also completed the acquisition of Veterinary Pathology Group in 2025, although this did not significantly impact its financial results. Additionally, Zoetis has been actively managing its costs, with restructuring charges and acquisition-related costs totaling $77 million in the second quarter of 2026, compared to $30 million in the same period of 2025.
Operationally, Zoetis reported a decrease in its employee headcount, reflecting ongoing cost-reduction initiatives. The company maintained a strong cash position, with cash and cash equivalents totaling $1.476 billion as of June 30, 2026, down from $2.450 billion at the end of 2025. The company’s long-term debt remained stable at $9.048 billion. Looking ahead, Zoetis anticipates continued challenges in the competitive landscape, particularly in the companion animal segment, but remains optimistic about growth opportunities in livestock products and international markets. The company plans to leverage its diverse product portfolio and ongoing investments in research and development to drive future growth.
About Zoetis Inc.
Zoetis Inc. is a global leader in animal health, specializing in the discovery, development, manufacturing, and commercialization of medicines, vaccines, diagnostics, biodevices, and genetic tests for companion animals and livestock. Its diversified portfolio serves veterinarians, pet owners, and livestock producers worldwide, emphasizing innovation, product lifecycle extension, and regulatory compliance to improve animal welfare, food safety, and sustainability across major markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov